Multidrug-resistant tet(X)-containing hospital isolates in Sierra Leone by Leski, Tomasz A et al.
GA
S
M
T
S
a
b
c
d
A
R
A
K
F
t
T
M
M
T
1
e
a
o
h
u
b
a
e
e
i
p
t
C
c
o
(
[
c
o
0
hARTICLE IN PRESS ModelNTAGE-4087; No. of Pages 4
International Journal of Antimicrobial Agents xxx (2013) xxx– xxx
Contents lists available at SciVerse ScienceDirect
International  Journal  of  Antimicrobial  Agents
jou rn al hom epage : ht tp : / /www.e lsev ier .com/ locate / i jant imicag
hort  communication
ultidrug-resistant  tet(X)-containing  hospital  isolates  in  Sierra  Leone
omasz  A.  Leskia, Umaru  Bangurab,c, David  Henry  Jimmyb,c, Rashid  Ansumanab,c,
tephen  E.  Lizewskid, David  A.  Stengera, Chris  Rowe  Taitt a,  Gary  J.  Voraa,∗
Center for Bio/Molecular Science and Engineering, Naval Research Laboratory, Washington, DC, USA
Mercy Hospital Research Laboratory, Kulanda Town, Bo, Sierra Leone
School of Environmental Sciences, Njala University, Bo, Sierra Leone
Infectious Diseases Research Directorate, Naval Medical Research Center, Silver Spring, Maryland, USA
a  r  t  i  c  l e  i  n  f  o
rticle history:
eceived 18 October 2012
ccepted 9 April 2013
a  b  s  t  r  a  c  t
The  tet(X)  gene  encodes  a ﬂavin-dependent  monooxygenase  that confers  resistance  to  all  clinically  rele-
vant  tetracycline  antibiotics  including  tigecycline.  It  has only  previously  been  identiﬁed  in environmental
and  non-human  pathogenic  bacteria.  To  investigate  levels  of multidrug  resistance  in Bo, Sierra  Leone,  a
molecular  epidemiological  study  was  conducted  using  an  antimicrobial  resistance  determinant  microar-eywords:
lavin-dependent monooxygenase
et(X)
igecycline
ultidrug resistance
olecular epidemiology
ray (ARDM),  PCR  and  DNA  sequencing.  The  study  found  that  21%  of isolates  from  Mercy  Hospital  (Bo,
Sierra  Leone)  were  tet(X)-positive,  all of  which  originated  from  urinary  specimens.  Use  of molecular  epi-
demiological  surveillance  tools  has  provided  the ﬁrst  evidence  of tet(X)-containing  multidrug-resistant
Gram-negative  hospital  isolates  in  a  hospital  in  Sierra  Leone.
Published by Elsevier B.V. on behalf of International Society of Chemotherapy.
etracycline
. Introduction
Tetracyclines are useful antibiotics owing to their clinical
fﬁcacy, low cost, oral availability, broad-spectrum antibacterial
ctivity and relative ease of synthesis [1]. However, extensive use
ver the past 60 years or more for treating bacterial infections in
umans, agricultural applications, aquaculture and non-antibiotic
se has been accompanied by a commensurate increase in the num-
er and spread of tetracycline resistance genes [1,2]. To date, there
re three known mechanisms of tetracycline resistance (active
fﬂux, ribosomal protection and enzymatic modiﬁcation) and ca. 43
stablished tetracycline resistance genes [2]. Whilst the vast major-
ty of these genes encode efﬂux (n = 27) and ribosomal protection
roteins (n = 12), three [tet(X), tet(34) and tet(37)]  are unique in that
hey encode enzymes that inactivate tetracycline antibiotics [2].
hemical modiﬁcation of tetracycline was ﬁrst described in tet(X)-
ontaining bacteria and has since become the most studied and
nly model for this speciﬁc mechanism of action [3–7].
The tet(X) gene encodes a ﬂavin-dependent monooxygenase
TetX) that requires NADPH and oxygen for enzymatic activityPlease cite this article in press as: Leski TA, et al. Multidrug-resistant tet(X)
(2013), http://dx.doi.org/10.1016/j.ijantimicag.2013.04.014
4,5,7]. In vitro and in vivo assays have demonstrated that TetX
an catalyze the inactivation of a variety of tetracyclines (e.g.
xytetracycline, chlortetracycline, demeclocycline, doxycycline,
∗ Corresponding author. Tel.: +1 202 767 0394; fax: +1 202 767 9594.
E-mail address: gary.vora@nrl.navy.mil (G.J. Vora).
924-8579/$ – see front matter. Published by Elsevier B.V. on behalf of International Soci
ttp://dx.doi.org/10.1016/j.ijantimicag.2013.04.014minocycline, tetracycline) [7] with perhaps the most important
being tigecycline, a novel third-generation glycylcycline deriva-
tive of tetracycline that was  designed to circumvent the most
commonly encountered efﬂux and ribosomal protection resistance
mechanisms [8]. Although presence of the tet(X) gene in a bac-
terial pathogen could herald the clinical failure of all tetracycline
antibiotics, as yet there has been no observed clinical impact as the
tet(X) gene is seemingly rarely found. It has only been previously
documented in obligate anaerobes such as Bacteroides [3,5,9,10],
an agricultural soil bacterium (Sphingobacterium sp.) [11], piggery
manure-treated soil [12] and within activated sludge from sewage
treatment plants [13]. Thus, whilst the absence of tet(X) from aer-
obic human pathogens is notable, it is also viewed as a temporary
condition as it has been suggested that tetracycline resistance genes
‘unique’ to environmental bacteria will eventually be discovered in
human pathogens [2].
In this study, a novel molecular epidemiological screening tool,
the antimicrobial resistance determinant microarray (ARDM), as
well as additional conﬁrmatory assays were used to provide the ﬁrst
description of tet(X)-containing multidrug-resistant (MDR) hospi-
tal isolates.
2. Materials and methods-containing hospital isolates in Sierra Leone. Int J Antimicrob Agents
2.1. Collection and identiﬁcation of bacterial isolates
A total of 52 clinical stool, semen, blood and urine samples
(collected from November 2010 to September 2011 at Mercy
ety of Chemotherapy.
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ospital, Bo, Sierra Leone) were used to inoculate agar medium
Biotec, Lab21 Healthcare Ltd., Bridport, UK). Single colony isolates
ere harvested from each and were subjected to total genomic DNA
xtraction using a MasterPureTM Complete DNA and RNA Puriﬁca-
ion Kit (Epicentre Biotechnologies, Madison, WI). Bacterial isolates
ere then identiﬁed based on PCR ampliﬁcation and sequencing of
 16S rDNA amplicon that spanned the V3 and V4 variable regions
14] and the rpoB or gyrA gene as previously described [15,16]. For
he preliminary identiﬁcations, the obtained 16S rDNA sequences
ere used to classify each isolate using the Naïve Bayesian Clas-
iﬁer available through Ribosomal Database Project (release 10)
http://rdp.cme.msu.edu/classiﬁer/classiﬁer.jsp) [17].
.2. Antibiotic susceptibility testing
The sensitivity of a subset of the hospital isolates to
zithromycin, tetracycline, gentamicin, kanamycin, oﬂoxacin,
mpicillin/sulbactam, ampicillin, sulﬁsoxazole, penicillin, erythro-
ycin, ciproﬂoxacin and doxycycline was determined using a disk
iffusion method according to Mercy Hospital and Clinical and
aboratory Standards Institute (CLSI) guidelines. Brieﬂy, single iso-
ated colonies grown on agar medium (Biotec, Lab21 Healthcare
td.) were transferred into tubes containing 0.9% sterile saline solu-
ion and were emulsiﬁed. This inoculum was then used to streak
ueller–Hinton agar plates (Biotec, Lab21 Healthcare Ltd.), and
ntibiotic-containing disks (Hardy Diagnostics, Santa Maria, CA)
ere dispensed onto the agar surface. All plates were incubated
or 18 h at 37 ◦C and the diameters of inhibition zones were then
easured and interpreted.
.3. Antimicrobial resistance determinant microarray
ybridisation and data analysis
The ARDM v.1 is a custom-designed CustomArray microarray
4 × 2K chips) that contains 2240 oligonucleotide probes target-
ng 239 unique genes that confer resistance to 12 classes of
ntimicrobial compounds (CustomArray, Bothell, WA)  [18]. To
egin processing samples for ARDM hybridisation, 10 ng of each
enomic DNA extract was subjected to whole-genome ampliﬁca-
ion using a GenomiPhi V2 Reagent Kit (GE Healthcare, Piscataway,
J) according to the manufacturer’s instructions, with the reaction
ixture incubated for 90 min  at 30 ◦C and subsequently at 65 ◦C
or 10 min  to stop the reaction. Then, 2 g of the resulting high-
olecular-weight amplicons were fragmented for 1 min  at 37 ◦C
sing Fragmentation Reagent (DNase I, 0.045 U/g DNA) and Frag-
entation Buffer (GeneChip® Resequencing Assay Kit; Affymetrix,
anta Clara, CA) in a total reaction volume of 60 L. The enzyme
as subsequently inactivated by incubation at 95 ◦C for 10 min. The
mpliﬁed and fragmented DNA was then puriﬁed using DNA Clean
 ConcentratorTM-5 Kit (Zymo Research, Irvine, CA) and labelled
sing the ULS Platinum BrightTM Biotin Nucleic Acid Labeling Kit
Kreatech Diagnostics, Durham, NC) according to the manufac-
urer’s instructions (total reaction volume of 10 L). Following
uriﬁcation of the labelled fragments using the kit’s KREApure
olumns, the samples were hybridised to the ARDM according to
he manufacturer’s instructions, with the following changes to the
tandard protocol: (i) both prehybridisation and hybridisation tem-
eratures were increased to 60 ◦C; and (ii) a highly polymerised
treptavidin–peroxidase conjugate S104PHRP (Fitzgerald Indus-
ries, North Acton, MA)  was used in place of the CustomArray Biotin
abeling Solution. All microarrays were processed and interrogated
lectrochemically using an ElectraSense® reader (CustomArray)Please cite this article in press as: Leski TA, et al. Multidrug-resistant tet(X)
(2013),  http://dx.doi.org/10.1016/j.ijantimicag.2013.04.014
nd the data were analysed with custom-developed Perl scripts
sing the following criteria for positive/negative signal determi-
ations: individual probes were designated positive when their
ignal exceeded a threshold deﬁned as the average signal of all PRESS
imicrobial Agents xxx (2013) xxx– xxx
microarray probes (excluding the top 5%) plus three standard devi-
ations. Each gene was  considered present if ≥40% of its probes
provided positive signal determinations.
2.4. Conﬁrmatory PCR and DNA sequencing
Conﬁrmatory PCR and screening of the hospital isolates for
the tet(X), tet(X1) and tet(X2) genes was  performed by PCR
ampliﬁcation of internal segments of each gene using previ-
ously published primers and cycling conditions [9,14]. All PCR
amplicons were size-conﬁrmed by electrophoresis using 1.2%
FlashGelTM DNA Cassettes (Lonza, Walkersville, MD)  and the
identities of the detected amplicons were further veriﬁed by
DNA sequencing (Euroﬁns MWG  Operon, Huntsville, AL). Full-
length tet(X) and tet(X2) gene sequences from isolates SL-1 and
SL-20 were determined using the following additional primers
that were designed based on publicly available sequences:
tetX-III-F (5′-CCTGATGAATGGAAAAACCAAACGC-3′)/tetX-III-R
(5′-ACAATTGCTGAAACGTAAAGTCGGG-3′); tetX-V-F (5′-GCTT-
GAACCTGGTAAGAAGAAGTGG-3′)/tetX-V-R (5′-GCGTTCGTCCCAA-
TCGGAAA-3′); tetX-7-F (5′-TGGGCCATTTTTGAATGACAATGCG-
3′)/tetX-7-R (5′-TGTGTAGGTCAAGGGTTCCACCA-3′); and tetX-8-F
(5′-TGGGTTGGTGGATGCCTTGATATTG-3′)/tetX-8-R (5′-CGGCTGG-
CAAATTGGCGATGG-3′). Conﬁrmation of the terminal open reading
frame sequences and sequencing of the tet(X) ﬂanking regions was
performed using a DNA Walking SpeedUpTM Premix Kit (Seegene,
Seoul, South Korea) according to the manufacturer’s instructions.
3. Results and discussion
As a part of a larger study on the distribution of antimicro-
bial resistance determinants and level of multidrug resistance in
West Africa, we  began testing bacterial isolates collected from
Mercy Hospital in Bo, Sierra Leone, using the ARDM as a screening
tool. ARDM is capable of detecting 43 known tetracycline resis-
tance genes and an assortment of other determinants covering 12
classes of antibiotics. One of the ﬁrst isolates tested (urine iso-
late SL-4) revealed that 100% of the ARDM probes speciﬁc for the
tetracycline resistance genes tet(X) and tet(39) (which encodes a
tetracycline efﬂux pump) were found to be hybridisation-positive.
In addition, the analysis under stringent threshold settings identi-
ﬁed 17 other putative resistance genes under stringent threshold
settings known to confer resistance to trimethoprim (dfrA14),
sulfamethoxazole (sulI, sulII), quaternary ammonium compounds
(qacE1), macrolides (macB), streptomycin (strA, strB), amino-
glycosides [aac(3)-III, aac(6)-Ib family, aadB/ant(2′′)-1a, aadA1/A2
family, aphAI]  and -lactams (blaTEM, blaOXA-10 family) strongly
suggesting the likely MDR  nature of isolate SL-4.
As a response to this ﬁnding, we chose to screen all clinical
isolates using two previously described tet(X)-speciﬁc PCR assays
[9,19] and subsequent DNA amplicon sequencing to determine the
prevalence of tet(X) in this environment. The results demonstrated
that 11 (21%) of the 52 isolates were tet(X)-positive. All of the tet(X)-
positive strains had been isolated from clinical urine specimens.
DNA sequence analyses also revealed that 9 (82%) of the 11 tet(X)-
positive isolates were indeed tet(X), whilst 2 (18%) harboured the
tet(X2) orthologue [20]. None of the isolates tested harboured the
tet(X1) orthologue [20].
The identities of the 11 tet(X)-positive isolates were deter-
mined using PCR ampliﬁcation and sequencing of the 16S rRNA
and rpoB or gyrA genes using previously published primers and-containing hospital isolates in Sierra Leone. Int J Antimicrob Agents
methods [15,16]. Species-level identiﬁcation was obtained for
8 (73%) of the isolates. Of the three remaining isolates, SL-10
was identiﬁed to the genus-level, and SL-8 and SL-22 did not
yield rpoB and gyrA amplicons. Enterobacter cloacae, Comamonas
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Table 1
Summary of tet(X)-containing hospital isolates in Bo, Sierra Leone.
Isolate Isolation date Symptoms Isolation agar tet(X) allele Identiﬁcation ARDM proﬁlea MDR phenotypeb
SL-1 Nov. 2010 Abdominal pain
and painful
urination
Nutrient tet(X)c Enterobacter cloacae
(100)d
blaOXA-58, blaTEM-1, aac(3)-III, aadA1/A2
family, strA, strB, tet(39),  tet(B), tet(D),
qacE1,  sat2, sulII, dfrA1, dfrA14,  folAe
n.d.
SL-4  Dec. 2010 n.d. Nutrient tet(X) Comamonas
testosteroni (100)f
blaOXA-1, blaOXA-10/PSE-2, blaTEM-1,
aac(3)-III, aac(6′)-Ib, aac(6)-Ib, aadA1,
aadA1b,  aadB, ant(2′′)-Ia, aphAI,  strA,
strB,  macB, tet(39), qacE1, sulI, sulII,
dfrA1g
n.d.
SL-5  Dec. 2010 n.d. Sensitivity tet(X2) Escherichia coli (100)d blaCTX-M-3, blaTEM-10/MGH-1, blaTEM-1,
penA,  aadA1,  strA, strB, macA, macB,
mphA, mphK,  tet(39), tet(B), catA1, cmr,
qacE1,  sulI, sulII, dfrA14,  folAe,g
n.d.
SL-7  Dec. 2010 Frequent and
painful urination
and slight
discharge of pus
Nutrient tet(X) E. cloacae (98)d blaTEM-10/MGH-1, blaTEM-1, aadB,
ant(2′′)-Ia, aphAI, strA, strB, tet(39),
tet(A), qacE1, sulII, dfrA2g
n.d.
SL-8  Dec. 2010 Lower abdominal
pain, menstrual
irregularities
Sensitivity tet(X) Enterobacteriaceae
(100)h
n.t. n.d.
SL-9  Dec. 2010 Frequent urine,
lower abdominal
pain, vaginal
discharge
Sensitivity tet(X) E. cloacae (100)d ant(2′′)-Ia, strA, strB, tet(39),  tetS, sulIIg n.d.
SL-10  Dec. 2010 Painful urination CLED tet(X) Enterobacter sp. (90)d blaOXA-1, blaTEM-1, aac(6′)-Ib, strA, strB,
tet(39),  sulIIg
n.d.
SL-13 March 2011 Fever, frequent
urination, high
blood pressure
Nutrient tet(X) Klebsiella pneumoniae
(99)d
n.t. Yes
SL-15 April 2011 General body
pain, painful
urination
MacConkey tet(X) E. cloacae (97)d n.t. Yes
SL-20  April 2011 Fever, abdominal
pain
Nutrient tet(X2)c Delftia acidovorans
(99)f
aadA1b, strA, strB, macA, macB, tet(39),
tet(A),  tet(B), catA1, cmlA, cmr, qacE1,
sulI, sulIIe
Yes
SL-22 April 2011 Chest pain,
vaginal discharge
and itching,
swollen foot
Nutrient tet(X) Pseudomonadaceae
(100)h
n.t. Yes
MDR, multidrug-resistant; n.d., not documented; n.t., not tested; CLED, cysteine–lactose–electrolyte-deﬁcient agar.
a Additional drug resistance determinants identiﬁed using the antimicrobial resistance determinant microarray (ARDM).
b Tested isolates were found to be resistant to azithromycin, tetracycline, gentamicin, kanamycin, oﬂoxacin, ampicillin/sulbactam, ampicillin, sulﬁsoxazole, penicillin,
erythromycin, ciproﬂoxacin and doxycycline via susceptibility disk measurements. Tigecycline resistance was  not tested at the time of isolation.
c Full gene sequences deposited in GenBank under accession nos. JQ990987 and JQ990988.
d Derived from rpoB gene sequencing using the methods of Mollet et al. [15]. All identiﬁcations are genus- and species-level identiﬁcations. Numbers in parentheses
indicate  the percent sequence identity to reference sequences.
e Strain tested using ARDM v.2.0.
f Derived from gyrA gene sequencing using the methods of Tayeb et al. [16]. All identiﬁcations are species-level identiﬁcations. Numbers in parentheses indicate the percent
sequence identity to reference sequences.
ﬁcatio
t
r
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n
t
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d
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c
sg Strain tested using ARDM v.1.0.
h Derived from 16S rDNA sequencing. Number in parenthesis indicates the identi
estosteroni, Escherichia coli, Klebsiella pneumoniae, Delftia acidovo-
ans, Enterobacter sp. and other members of Enterobacteriaceae
nd Pseudomonadaceae harboured the tet(X) gene. Thus, tet(X) has
ow been found in nosocomial pathogens known to cause urinary
ract infections and associated complications. The tet(X)-containing
solate SL-22 (a pseudomonad) was of particular interest as this
nding corroborated the previously unpublished observation of a
inocycline-resistant tet(X3)-containing Pseudomonas aeruginosa
linical isolate from Japan (GenBank accession no. AB097942) and
uggested that clinically relevant pseudomonads may  also play a
ole in the dissemination of the tet(X) gene and its orthologues.
lso important, ARDM-based genotypic evidence (strains SL-1,
L-5, SL-7, SL-9, SL-10, SL-20) and antibiotic susceptibility testing-
ased phenotypic evidence (strains SL-13, SL-15, SL-20, SL-22)
emonstrated that 10 of the 11 tet(X)-containing isolates harbouredPlease cite this article in press as: Leski TA, et al. Multidrug-resistant tet(X)
(2013), http://dx.doi.org/10.1016/j.ijantimicag.2013.04.014
ultidrug resistance determinants or were indeed MDR  (Table 1).
These results provide the ﬁrst description of tet(X)- and tet(X2)-
ontaining bacteria isolated from clinical specimens. As there were
ome procedural constraints regarding the collection of urinen conﬁdence threshold. Both identiﬁcations are family-level identiﬁcations.
specimens in November and December of 2010, we  cannot be
certain whether the identiﬁed tet(X)-containing bacteria collected
during this timeframe were assigned causative agents of disease,
commensal organisms or hospital contaminants. However, (i) all
of the tet(X)-containing isolates were from urine collections, (ii)
the majority of isolates belonged to bacterial species and families
known to harbour human urinary tract pathogens, (iii) no other
organisms were isolated from these specimens on non-selective
media and (iv) accepted human pathogens containing tet(X) were
also isolated in March and April of 2011 (after procedural con-
straints had been ameliorated), suggesting that these were true
clinical isolates containing tet(X).
Despite having been found in only obligate anaerobes and envi-
ronmental bacteria, demonstration of tet(X) and its orthologues
in these hospital isolates is not surprising considering the size-containing hospital isolates in Sierra Leone. Int J Antimicrob Agents
of the environmental reservoir for tetracycline resistance genes
and the relative ease of lateral genetic transmission between bac-
terial species. For example, analyses of the DNA sequences (ca.
150 bp) ﬂanking the 3′ end of the tet(X) alleles in strains SL-1 and
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L-20 revealed that they were identical to sequences previously
ound in a number of conjugative transposons [e.g. Tn4351 from
acteroides fragilis (accession no. M37699) and CTnDOT from Bac-
eroides thetaiotaomicron (accession no. AJ311171)] that harbour
he tet(X) gene. Thus, as seen previously [4,11,20], these ﬁndings
lso suggest that these tet(X) genes likely reside in mobilisable
ransposons or transposon-like elements.
Tigecycline resistance is not currently tested for at Mercy
ospital, and a survey of independent pharmacies and hospital
ispensaries in Bo indicated that none had access to Tygacil®
tigecycline IV; Pﬁzer Inc.). However, 87% of pharmacies readily
ispensed other tetracycline antibiotics without requiring a pre-
cription. Thus, the positive selection pressure that results from
he continuous application of tetracycline antibiotics in such sett-
ngs may  serve to maintain and spread the tetracycline resistance
eterminants identiﬁed in this study [tet(X), tet(X2),  tet(39),  tet(B),
et(A), tet(S)].
The fact that 21% of the isolates tested in this study were shown
o harbour tet(X) suggests that the presence of this resistance gene
n hospital isolates is not a rare occurrence and that it is being
eadily circulated in Sierra Leone. The spread of this gene within
osocomial pathogens has potentially signiﬁcant implications as it
ay  portend eventual clinical failure of all tetracycline antibiotics
n this region.
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